Advances in Immunotherapy for Melanoma: A Comprehensive Review

Figure 3

Different vehicles could bind to tumor antigens and adjuvants resulting in antigen-presenting to dendritic cells (DCs). Once these vehicles are absorbed, both the antigen and the adjuvant will be released and degraded, leading to acceleration of the maturation of DCs as well as MHC molecules located on the cell surface that present the antigen. This will allow binding to CD8⁺ T cells that are activated, proliferated, and generated an antitumor response. MC: major histocompatibility complex; TCR: T cell receptor.